Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies



Rating:

Share or cite this content

Citations should be made in the following way:
S. da Costa Martins (Covilhã, Portugal), E. Tinoco (Vila Nova de Gaia, Portugal), B. Cabrita (Matosinhos, Portugal), D. Machado (Vila Nova de Gaia, Portugal), I. Franco (Vila Nova de Gaia, Portugal), I. Ladeira (Vila Nova de Gaia, Portugal), I. Pascoal (Vila Nova de Gaia, Portugal), R. Lima (Vila Nova de Gaia, Portugal), S. Valente (Covilhã, Portugal). Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study. 3727

Member's Comments

No comment yet.

Related content which might interest you: Mepolizumab reduces nasal symptoms in asthmatic patients with chronic rhino-sinusitis and nasal polyposis: a 12 months real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Treatment of nasal polyposis in aspirine sensitive asthma Source: Eur Respir J 2001; 18: Suppl. 33, 425s Year: 2001 Dupilumab improves all ACQ-5 individual items in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma: results from a phase 2a trial Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSwNP) Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017 Late Breaking Abstract - Real-life rapidity of dupilumab effects on symptom control, lung function and prednisone intake in patients with severe eosinophilic asthma and nasal polyposis Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Impact of mepolizumab in severe asthma with nasal polyps Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Rhinitis, nasosinusal polyposis and asthma: clinical aspects Source: ISSN=1025-448x, ISBN=1-904097-19-17, page=101 Year: 2001 The clinical relationship of nasal polyposis to asthma and other pathologies in the French population Source: Eur Respir J 2003; 22: Suppl. 45, 114s Year: 2003 Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Nonallergic rhinitis, sinonasal polyposis and asthma Source: Eur Respir J 2003; 22: Suppl. 45, 108s Year: 2003 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Nasal polyposis, analgesics intolerance and asthma Source: Eur Respir J 2001; 18: Suppl. 33, 428s Year: 2001 Aspirin-induced urticaria/angioedema without respiratory symptoms in severe asthmatics with nasal polyposis Source: Eur Respir J 2002; 20: Suppl. 38, 512s Year: 2002 Impact of biologic therapy in severe asthma with nasal polyps Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Real-world evidence of reported symptoms and quality of life burden associated with chronic rhinosinusitis with nasal polyposis and comorbid asthma status Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases Year: 2021 Effect of mepolizumab on chronic rhinosinusitis symptoms and nasal hypersensitivity in patients with or without nasal polyps Source: Virtual Congress 2020 – Asthma management: role of biomarkers and comorbidities Year: 2020 Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020